Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects

Background  In a previous study a new hydrosoluble nail lacquer (P‐3051) containing 8% ciclopirox (CPX) showed higher nail penetration compared to a water‐insoluble 5% amorolfine (MRF) lacquer. To our knowledge, in vivo human data on a similar topic are not available.

[1]  D. Monti,et al.  Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation , 2011, The British journal of dermatology.

[2]  D. Monti,et al.  Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity , 2010, The British journal of dermatology.

[3]  A. Tosti,et al.  An innovative water‐soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  R. Neubert,et al.  Different physicochemical properties of antimycotic agents are relevant for penetration into and through human nails. , 2006, Die Pharmazie.

[5]  H. Korting,et al.  Nail Penetration of Sertaconazole with a Sertaconazole-Containing Nail Patch Formulation , 2006, American journal of clinical dermatology.

[6]  D. Monti,et al.  In Vitro Transungual Permeation of Ciclopirox from a Hydroxypropyl Chitosan-Based, Water-Soluble Nail Lacquer , 2005, Drug development and industrial pharmacy.

[7]  R Baran,et al.  Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  B. Cribier,et al.  Terbinafine in the treatment of onychomycosis: a review of its efficacy in high‐risk populations and in patients with nondermatophyte infections , 2004, The British journal of dermatology.

[9]  O. Schofield,et al.  Terbinafine-induced subacute cutaneous lupus erythematosus. , 2004, Acta dermato-venereologica.

[10]  Aditya K. Gupta,et al.  The use of topical therapies to treat onychomycosis. , 2003, Dermatologic clinics.

[11]  K. Tintelnot,et al.  Antifungal Agents , 2003, Special Topic.

[12]  S. Murdan.  Drug delivery to the nail following topical application. , 2002, International journal of pharmaceutics.

[13]  Aditya K. Gupta,et al.  Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. , 2000, Journal of the American Academy of Dermatology.

[14]  M. Bohn,et al.  Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. , 2000, Journal of the American Academy of Dermatology.

[15]  Roberts.  Onychomycosis: current treatment and future challenges , 1999, The British journal of dermatology.

[16]  J. Marty.  Amorolfine nail lacquer: a novel formulation , 1995 .

[17]  A. Polak.  Preclinical data and mode of action of amorolfine , 1992, Dermatology.

[18]  G. Klecak,et al.  Loceryl® nail lacquer—realization of a new galenical approach to onychomycosis therapy , 1992, Clinical and experimental dermatology.

[19]  T. Franz.  Absorption of amorolfine through human nail. , 1992, Dermatology.